At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 951 enrolled
Drug / intervention
fesoterodine fumarate +2 moredrug
Likely dose
fesoterodine fumarate 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.
In Brief
A Phase 2 clinical trial evaluating fesoterodine fumarate and Placebo for Overactive Bladder. Completed, enrolled 951 participants across 65 sites in 4 countries.
Detailed Summary
To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesHong Kong, Japan, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedNov 21, 2007
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.6 years ago
Interventions
fesoterodine fumaratedrug
8mg tablets OD for 12 weeks
Placebodrug
Corresponding placebo tablets OD for 12 weeks
fesoterodine fumaratedrug
4mg tablets OD for 12 weeks